Member Info for MALTBY2002

Ask yourself why a person with such a personal and professional back story should now concentrate her efforts on the oncology work of a small UK bio company based in Wetherby and Cambridge.

Yes it’s right to draw a distinction here between therapeutics and diagnostics regarding expectations and timelines. Al has been criticised for over optimistic timelines regarding the rolling out of the LFD but he has been let down badly by factors outside its control not least the actions of HMG. When it comes to the science which AVCT can control it has produced one of the most accurate tests on the market. With the cancer trials there is much less opportunity for outside factors like HMG intervention to impede progress. Hopefully there will be fewer unnecessarily spiteful comments aimed in the direction of Al and his wonderful team as they progress the company over the coming months to something which potentially could have a global impact

Good to see the SP finally responding to the potential that a few of us have known about for some time. Little doubt now that this potential with fairly regular news flow is now becoming more widely known

No surprise it would be LUFC given AVCT’s close links to Leeds University

In relation to the query regarding the possible squeeze on profit margins due to a saturated market, it was made very clear in the Presentation that our higher quality test would enable us to set a higher price without affecting market share

In the slide on LFD Medusa was mentioned in the last bullet point. Al emphasised that it’s potential significance was more important than the other manufacturers referenced. HUA for Medusa appears to be inevitable and possibly imminent and it is highly unlikely news of this is in the present SP.

Have you ever been positive about AVCT Roly? You have zero credibility. Welcome to the green box

Abingdon producing batched products for sale now

Very pleased with progress to date

3 more AVA6k sites coming on line

It was the type of report that could have been anticipated but no worse for that. The 2 big takeaways for me was the £37 million cash available and the second and third doses administered at the Royal Marsden

Further reference to the price of our LFD being above cheaper alternatives because of the quality of our product.

All good news on the 2 major inflection points on the LFD roll out and AVA6k. Yes timelines have been missed and still awaiting HUA which is outside AVCT control but the upside is these tests will be used over a much longer period. Looking forward to the Presentation

Second and third doses of AVA6k given. All going well at Royal Marsden then

Yes good find further reinforcing that AVCT is far more than just a Covid play and the adaptability of the affimer platform

Astrea, DVRG and Point all coming out with news today regarding developing either affimers or Precision.

Away from the mindless drivel we have again been subjected to come 2 pieces of news today from Point and DVRG again showing how affimers can be effectively used and the potential revenue Avct could earn once these trials have been successfully completed

Tectonic Gold (LON:TTAU) (@tectonic_gold) Tweeted:
#TTAU Second hole underway

#Gold #Copper https://t.co/RGRjP8jSFx

Fuller 22 minute version. Sounds encouraging

Tectonic Gold (LON:TTAU) (@tectonic_gold) Tweeted:
#TTAU Video Interview:

@AmonkMonkey caught up with CEO Brett Boynton to update on the work programme & newsflow to come

Thousands of orders. Just posted on Twitter

https://mobile.twitter.com/davball15/status/1434879462689103879/photo/1